Headquartered in Miami, FL·Fiscal year ends December·NASDAQ: PLSE·pulsebiosciences.com
About Pulse Biosciences
Pulse Biosciences is a bioelectric medicine company developing and commercializing its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology, branded nPulse. The technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue.
The company's main focus is atrial fibrillation (AF), pursued through two devices:
- The nPulse Cardiac Catheter System for endocardial AF ablation. Its U.S. IDE pivotal study, NANOPULSE-AF, completed enrollment of 169 evaluable patients, and a CE Mark is targeted for Q4 2027.
- A surgical clamp for concomitant surgical AF ablation, being evaluated in the NANOCLAMP-AF U.S. IDE pivotal study.
The company currently generates modest product revenue from the Vybrance Percutaneous Electrode System for soft tissue ablation, which is in a controlled commercial launch with a limited customer base. Vybrance is also being studied for benign thyroid nodules in the PRECISE-BTN study.
Pulse funds operations largely through equity raised under at-the-market (ATM) programs. As of September 30, 2026, it held $189.2 million in cash, cash equivalents and marketable securities. Updated
Pre-Market Stock Futures: Futures are trading lower as we prepare to close out the trading week. What a difference a day can make. After a blockbuster rally on Wednesday, the stock market…
Pulse Biosciences is a bioelectric medicine company developing and commercializing its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology, branded nPulse. The technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue.
What is the PLSE stock price target?
The Wall Street consensus 12-month price target for PLSE is $67.67.